PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
30361780-7	2018	All of the six drugs examined, including amitriptyline, fluoxetine, imipramine, irinotecan, ondansetron, and verapamil, were inhibitors of OCT1/2-mediated morphine uptake.	Ondansetron	92-103	solute carrier family 22 member 1	Homo sapiens	139-143	
23835420-5	2013	OCT1-mediated morphine uptake was abolished by common loss-of-function polymorphisms in the OCT1 gene and was strongly inhibited by drug-drug interactions with irinotecan, verapamil and ondansetron.	Ondansetron	186-197	solute carrier family 22 member 1	Homo sapiens	0-4	
23835420-5	2013	OCT1-mediated morphine uptake was abolished by common loss-of-function polymorphisms in the OCT1 gene and was strongly inhibited by drug-drug interactions with irinotecan, verapamil and ondansetron.	Ondansetron	186-197	solute carrier family 22 member 1	Homo sapiens	92-96	
27676604-6	2017	Genetic polymorphisms in OCT1 and OCT2 affected ipratropium uptake and clinically relevant concentration of ondansetron and pyrithiamine inhibited ipratropium uptake via MATEs by more than 90%.	Ondansetron	108-119	solute carrier family 22 member 1	Homo sapiens	25-29	
20921968-0	2012	Effects of OCT1 polymorphisms on the cellular uptake, plasma concentrations and efficacy of the 5-HT(3) antagonists tropisetron and ondansetron.	Ondansetron	132-143	solute carrier family 22 member 1	Homo sapiens	11-15	
20921968-3	2012	Both tropisetron and ondansetron inhibited ASP(+) uptake in OCT1-overexpressing HEK293 cells.	Ondansetron	21-32	solute carrier family 22 member 1	Homo sapiens	60-64	
20921968-7	2012	Nevertheless, OCT1 genotypes correlated with pharmacokinetics (n=45, P<0.05) and clinical efficacy (n=222, P<0.02) of ondansetron, the effect size of OCT1 genotypes on pharmacokinetics and efficacy was greater for tropisetron than for ondansetron.	Ondansetron	124-135	solute carrier family 22 member 1	Homo sapiens	14-18	
20921968-7	2012	Nevertheless, OCT1 genotypes correlated with pharmacokinetics (n=45, P<0.05) and clinical efficacy (n=222, P<0.02) of ondansetron, the effect size of OCT1 genotypes on pharmacokinetics and efficacy was greater for tropisetron than for ondansetron.	Ondansetron	241-252	solute carrier family 22 member 1	Homo sapiens	14-18	
20921968-8	2012	In conclusion, in addition to the known effects of CYP2D6, OCT1 deficiency may increase efficacy of tropisetron and potentially of ondansetron by limiting their hepatic uptake.	Ondansetron	131-142	solute carrier family 22 member 1	Homo sapiens	59-63